SFC

Découvrez l'article du mois d'avril des Archives of Cardiovascular Diseases, la revue scientifique en anglais de la SFC : 
Left atrial cardiomyopathy: Pathophysiological insights, assessment methods and clinical implications 
Sandro Ninni, Vincent Algalarrondo, Fabien Brette, Gilles Lemesle, Jérémy Fauconnier, on behalf of the Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC)

Abstract


Atrial cardiomyopathy is defined as any complex of structural, architectural, contractile or electrophysiological changes affecting atria, with the potential to produce clinically relevant manifestations.

Most of our knowledge about the mechanistic aspects of atrial cardiomyopathy is derived from studies investigating animal models of atrial fibrillation and atrial tissue samples obtained from individuals who have a history of atrial fibrillation.

Several noninvasive tools have been reported to characterize atrial cardiomyopathy in patients, which may be relevant for predicting the risk of incident atrial fibrillation and its related outcomes, such as stroke.

Here, we provide an overview of the pathophysiological mechanisms involved in atrial cardiomyopathy, and discuss the complex interplay of these mechanisms, including aging, left atrial pressure overload, metabolic disorders and genetic factors.

We discuss clinical tools currently available to characterize atrial cardiomyopathy, including electrocardiograms, cardiac imaging and serum biomarkers.

Finally, we discuss the clinical impact of atrial cardiomyopathy, and its potential role for predicting atrial fibrillation, stroke, heart failure and dementia. Overall, this review aims to high-light the critical need for a clinically relevant definition of atrial cardiomyopathy to improve treatment strategies.

Nos suggestions d’actualités

Les actualités Cardio Online

Muvalaplin : nouvel inhibiteur de la lp(a) par voie orale

21 novembre 2024

Pas de supériorité d’un système d’aide à la décision pour optimiser les thérapies hypolipémiantes dans le post SCA

21 novembre 2024

Efficacité et sécurité d’emploi de l’obicetrapib, un nouvel inhibiteur de la CETP

21 novembre 2024

Zerlasiran, encore un nouvel antiLp(a) en développement

21 novembre 2024

L’edoxaban pour la prévention de thrombose valvulaire

20 novembre 2024

21/11/2024
Actualités Communautés
Newsletter

Newsletter de la SFHTA - Novembre 2024

21/11/2024
Actualités Congrès
Congrès

Impact environnemental de la cardiologie : Participez à notre enquête nationale !

20/11/2024
Actualités Communautés
Communautés

Congrès FCPC 2027 et 2028 : Appel à candidatures